rigel pharmaceuticals inc
(RIGL:NASDAQ GS)
Executive Profile*
James M. GowerChairman, Chief Executive Officer and Member of Finance Committee, Rigel Pharmaceuticals, Inc. |
| Age | Total Calculated Compensation | This person is connected to 7 board members in 1 different organizations across 2 different industries. See Board Relationships |
| 63 | $2,300,274 As of Fiscal Year 2012 |
Background*
Mr. James M. Gower has been the Chief Executive Officer of Rigel Pharmaceuticals Inc. since January 1997 and its Chairman since October 2001. Mr. Gower serves as an Advisor of VantagePoint Venture Partners. He served as President at Rigel Pharmaceuticals, Inc. since January 1997. From 1992 to March 1996, he served as the President and Chief Executive Officer of Tularik, Inc. He held several positions with Genentech, Inc., as Senior Vice President, responsible for sales, ...
Corporate Headquarters*1180 Veterans BoulevardSouth San Francisco, California 94080 United States Phone: 650-624-1100 Fax: 650-624-1101 Board Members Memberships*1996-N/A Former Director 1997-Present Chairman, Chief Executive Officer and Member of Finance Committee
Education*BS University of Tennessee System, The MBA University of Tennessee System, The
Other Affiliations* |
Annual Compensation*
Stock Options*
Total Compensation*
|
| Recently Viewed | |||
| RIGL:US | $4.45 USD | -0.13 |  |
COMPETITOR COMPENSATION
| Name | Position/ Company | Compensation |
| James A. Bianco M.D. | Principal Founder, Chief Executive Officer, President and Executive Director Cell Therapeutics, Inc. | $1.2M | Compensation as of Fiscal Year 2012. |
Post a JobJobs
Sponsored Financial Commentaries
Sponsored Links
To contact RIGEL PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
